CSL Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

CSL 1.12% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

1.1%

Temettü verimi

-0.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.6%
Gelecekteki Temettü Verimi	1.7%
Temettü Büyümesi	-5.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	51%

Son temettü ve geri alım güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CSL N MX piyasası için dikkate değer bir temettü ödemesi yapmıyor, bu nedenle ödemelerin istikrarlı olup olmadığını kontrol etmeye gerek yok.

Büyüyen Temettü: CSL N MX piyasası için dikkate değer bir temettü ödemiyor, bu nedenle ödemelerin artıp artmadığını kontrol etmeye gerek yok.

Piyasaya Karşı Temettü Getirisi

CSL Piyasaya Karşı Temettü Getirisi

CSL N temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CSL N)	1.1%
Pazarın Alt %25'i (MX)	0%
Pazarın En İyi %25'i (MX)	0%
Sektör Ortalaması (Biotechs)	0%
Analist tahmini (CSL N) (3 yıla kadar)	1.7%

Önemli Temettü: CSL N şirketinin temettüsü ( 1.12% ), MX pazarındaki temettü ödeyenlerin en alttaki %25'ine ( 2.66% ) kıyasla dikkate değer değil.

Yüksek Temettü: CSL N 'in temettüsü ( 1.12% ), MX piyasasındaki temettü ödeyenlerin en üst %25'ine ( 7.15% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CSL N MX piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CSL N MX piyasası için dikkate değer bir temettü ödemiyor.

CSL Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Upcoming dividend of US$1.18 per share

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought Mex$939k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold Mex$87m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin